Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
J Natl Compr Canc Netw. 2010 Oct;8(10):1219-22. doi: 10.6004/jnccn.2010.0089.
All breast carcinomas must originate within the ductal/lobular system as carcinoma in situ, but only a subset of these lesions progress to invasive carcinoma. Although pathologic evaluation of the extent of ductal carcinoma in situ (DCIS), the distance to margins, and the degree of margin involvement provides an estimation of the likelihood of residual disease, the amount of disease in the remaining breast cannot be predicted with certainty. Factors other than residual disease may be more important in determining whether patients with DCIS survive or succumb to breast cancer, including biologically new ipsilateral cancers, contralateral cancers, and the degree of resistance of the normal stroma to invasion.
所有乳腺癌都必须起源于导管/小叶系统中的原位癌，但这些病变中只有一部分进展为浸润性癌。尽管对导管原位癌（DCIS）的范围、切缘距离和切缘受累程度的病理评估提供了对残留疾病可能性的估计，但剩余乳房中的疾病量不能被确定地预测。除了残留疾病之外，其他因素可能在决定 DCIS 患者的生存或死于乳腺癌方面更为重要，包括同侧新的生物学癌症、对侧癌症以及正常基质对侵袭的抵抗力程度。
